Skip to main content

Table 2 Body composition and bone mineral density at the 3-month visit (time for randomisation)

From: Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months

  Treatment A (n= 22) Treatment B (n= 18)
Body mass index (kg/m2) 27.7 (6.4) 24.7 (3.7)
Fat mass (kg) 30.5 (12.9) 24.4 (7.5)
Fat mass index (kg/m2) 10.9 (4.8) 8.7 (2.9)
Fat (%) 38.8 (8.3) 35.7 (7.9)
Trunk:peripheral fat ratio 1.3 (0.3) 1.2 (0.4)
Trunk fat (kg) 16.4 (7.2) 13.9 (6.6)
Lean body mass (kg) 45.8 (8.8) 43.4 (9.0)
Appendicular lean mass (kg) 19.9 (4.4) 18.7 (4.4)
Fat-free mass (kg) 48.3 (9.1) 45.9 (9.4)
Fat-free mass index (kg/m2) 17.0 (2.5) 16.1 (2.1)
L2 to L4   
   Bone mineral density (g/cm2) 1.18 (0.19) 1.06 (0.14)
   Z score 0.68 (1.40) -0.66 (0.89)
   T score -0.31 (1.55) -1.26 (1.18)
Femoral neck   
   Bone mineral density (g/cm2) 0.98 (0.16) 0.92 (0.11)
   Z score 0.50 (1.04) -0.16 (0.79)
   T score -0.32 (1.25) -0.82 (0.95)
  1. Data presented as mean (standard deviation). Treatment A, methotrexate + sulphasalazine + hydroxychloroquine; treatment B, methotrexate +infliximab.